Tango Therapeutics, Inc. — Form 8-K
Filed November 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Tango Therapeutics reported 82% ORR and 88% 9-month PFS in Phase 1/2 study of vopimetostat plus daraxonrasib (Revolution Medicines' RAS inhibitor) in 2L/3L MTAP-deleted pancreatic cancer, with generally well-tolerated safety profile at dose vopimetostat 200 mg/daraxonrasib 100 mg daily. Company plans to initiate a registrational Phase 3 study in front-line MTAP-deleted pancreatic cancer in 1H 2027 and will discuss accelerated approval in second-line setting with regulators. Cash position stands at $977.5M as of Sept 30, 2026; R&D expenses increased to $48.9M (Q3 2026) vs $30.8M (Q3 2025) and $119.7M (9M 2026) vs $100.1M (9M 2025); net loss of $68.4M (Q3 2026) vs net income $15.9M (Q3 2025).
Why this rating
Strong clinical data and Phase 3 initiation are significant milestones; however, company remains pre-commercial with no approved products. Burn rate is elevated and cash runway requires success. Relative to $528M market cap, $977.5M cash is substantial but pancreatic cancer is niche market.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $21.75 ▲ 0.00% | at our read · unknown $21.75 | +10 min · unknown $21.46 ▼ 1.31% | +30 min · unknown $22.04 ▲ 1.33% | +1 hr · unknown $22.23 ▲ 2.18% | +4 hrs · unknown $22.73 ▲ 4.51% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.